Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X:
“Press release: positive PFS results from a Chinese phase 3 trial comparing Trastuzumab Pamirtecan (BNT323/DB-1303 – quite similar to T-DXd) to T-DM1 for HER2+ MBC. The DYNASTY-Breast02 trial is testing BNT323 as 1st cytotoxic therapy for HER2-low disease.”
Read the Full Article in BIOTECH.
More posts featuring Trastuzumab on OncoDaily.